1Mulsch A,Oelze M,Kloss S,et al.Effects of in vivo nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phosphoprotein in aorta[J].Circulation,2001,1
2Dupuis J,Lalonde G,Lemieux R,et al.Tolerance to intravenous nitro-glycerinin patients with congestive heart failure:role of increased intravascular volume,neurohumoral activation and lack of prevention with N-acetylcysteine[J].J Am Coll Cardiol,1990,16:92
3Needleman P,Johnson EM Jr.Mechanism of tolerance development to organic nitrates[J].J Pharmacol Exp Ther,1973,184:709-715.
4Boesgaard S,Aldershvile J,Poulsen HE,et al.Nitrate tolerance in vivo is not associated with depletion of arterial or venous thiol levels[J].Circ Res,1994,74:115-120.
5Parker JD,Farrell B,Fenton T,et al.Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin[J].Circulation,1991,84:2336-2345.
6Minamiyama Y,Imaoka S,Takemura S,et al.Escape from tolerance of organic nitrate by induction of cytochrome P450[J].Free Radic Biol Med,2001,31:1498-1508.
7Ratz JD,McGuire JJ,Anderson DJ,et al.Effects of the flavoprotein inhibitor,diphenyleneiodonium sulfate,on ex vivo organic nitrate tolerance in the rat[J].J Pharmacol Exp Ther,2000,293:569-577.
8Hofmann H,Schmidt HH.Thiol dependence of nitric oxide synthase[J].Biochemistry,1995,34:13443-13452.
9Seth P,Fung HL.Biochemical characterization of a membrane-bound enzyme responsible for generating nitric oxide from nitroglycerin in vascular smooth muscle cells[J].Biochem Pharmacol,1993,46:1481-1486.
10Wong PS,Eiserich JP,Reddy S,et al.Inactivation of glutathione s-transferases by nitric oxide-derived oxidants:exploring a role for tyrosine nitration[J].Arch Biochem Biophys,2001,394:216-228.
4Koerselman J,de Jaegere PP,Verhaar MC,et al.High blood pressure is inversely related with presence and extent of coronary collaterals.J Hum Hypertens,2005,19:809-817.
5Henry TD,Rocha-Singh K,Isner JM,et al.Intracoronary administration of recombinant hunan vascular endothelial growth factor to patients with coronary artery disease.Am Heart J,2001,142:872-880.
6Grundmann S,van Royen N,Pasterkamp G,et al.A new intrarterial delivery platform for pro-arteriogenic compounds to stimulate collateral artery growth via transforming growth factor-betal Release.J Am Coll Cardiol,2007,.50:351-358.
7Munzel T.Recent findings on nitratesl their action,bioactivation and development of tolerance.Dtsch Med Wochenschr,2008,133:2277-2282.
8Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST elebation myocardial infarction: a report of the American College of Cardiology/American Heart Associa- tion take force on practice guidelines:developed in collaboration with the canadian cardioeascular soeeity endorsed by the Amer- ican Academy of Familu Phudicians:2007 writing group to riv- iew new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elebation myocardial infarction,writing on behalf of the 2004 writing committee[J]. Circulation, 2008, 117 : 296 329.
